SAN DIEGO, April 29, 2021 (World NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a medical-phase biopharmaceutical business centered on the growth of novel oncology therapies,
Tag: Oncternal
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results
Interim Phase 1/2 results for cirmtuzumab with ibrutinib in MCL presented at ASH in December 2020 compare favorably to historical single-agent ibrutinib data (47% CR